According to the China Post Securities Research Report, medical insurance restrictions on proprietary Chinese medicines were clearly relaxed in the 2023 medical insurance catalogue, and the price reduction of Chinese medicines was moderate; under the demand for diagnosis and treatment caused by the epidemic and influenza, related products were released at an accelerated pace, and the reputation of traditional Chinese medicine has increased markedly in recent years, which can also drive the development of the product group. The traditional Chinese medicine sector is currently at a low level of valuation. It is optimistic that the hospital has sufficient evidence-based medical evidence, targets for drugs discussed by the government, and targets for continuous improvement in OTC sales and management of traditional Chinese medicines.